According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “
A number of other research firms also recently issued reports on NVZMY. Goldman Sachs Group downgraded NOVOZYMES A/S/S from a buy rating to a sell rating in a research note on Wednesday, April 1st. ValuEngine upgraded NOVOZYMES A/S/S from a sell rating to a hold rating in a research report on Saturday, March 14th. Finally, Credit Suisse Group downgraded NOVOZYMES A/S/S from an outperform rating to an underperform rating in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $61.00.
NOVOZYMES A/S/S (OTCMKTS:NVZMY) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.42. The firm had revenue of $558.75 million for the quarter. NOVOZYMES A/S/S had a return on equity of 26.90% and a net margin of 21.08%. On average, sell-side analysts expect that NOVOZYMES A/S/S will post 1.63 EPS for the current year.
NOVOZYMES A/S/S Company Profile
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.
Recommended Story: Nikkei 225 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.